BioCentury | Apr 15, 2013
Company News

Pharmacopeia, Texas Biotech deal

The companies will identify drug candidates for targets involved in diseases of the vascular endothelium, such as stroke and asthma. TXB will have access to PCOP's small molecule combinatorial chemistry libraries to identify lead compunds...
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

The FDA granted priority review status for TBX's NDA for its Novastan ( argatroban ) thrombin inhibitor. TBX and SmithKline-Beecham (Philadelphia, Penn.) last month agreed to market and co-develop Novastan in the U.S. and Canada as an...
BioCentury | Dec 13, 2010
Finance

Thelin's Last Breath

...requested an additional pivotal trial. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Dec 13, 2010
Clinical News

Thelin sitaxentan update

...should conduct an additional study. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
...Sept. 30 (see BioCentury, June, 18, 2007). Pfizer gained Thelin from its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Dec 11, 2010
Company News

Pfizer withdraws PAH drug

...that requested an additional study. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Oct 6, 2008
Company News

Castle Biosciences management update

...Diagnostic Hired: Derek Maetzold as president and CEO, formerly VP of marketing and sales at Encysive Pharmaceuticals Inc. WIR...
BioCentury | Jun 16, 2008
Company News

Encysive, Pfizer deal

...Encysive for $2.35 per share, or about $195 million in cash (see BioCentury, April 21). Encysive Pharmaceuticals Inc....
BioCentury | Apr 24, 2008
Distillery Therapeutics

This Week in Therapeutics

...of the U.S. Thelin sitaxsentan, an endothelin A receptor antagonist that Pfizer Inc. acquired from Encysive Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Company News

Encysive, Pfizer deal

...Pfizer completed its tender offer for Encysive, acquiring 69.1 million shares (85.3%) at $2.35 for a...
...to acquire the remaining shares at $2.35 via a merger agreement (see BioCentury, Feb. 25). Encysive Pharmaceuticals Inc....
BioCentury | Apr 14, 2008
Company News

Encysive, Pfizer deal

...Encysive. At April 7, there were 67.4 million shares (83%) tendered (see BioCentury, Feb. 25). Encysive Pharmaceuticals Inc....
Items per page:
1 - 10 of 310
BioCentury | Apr 15, 2013
Company News

Pharmacopeia, Texas Biotech deal

The companies will identify drug candidates for targets involved in diseases of the vascular endothelium, such as stroke and asthma. TXB will have access to PCOP's small molecule combinatorial chemistry libraries to identify lead compunds...
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

The FDA granted priority review status for TBX's NDA for its Novastan ( argatroban ) thrombin inhibitor. TBX and SmithKline-Beecham (Philadelphia, Penn.) last month agreed to market and co-develop Novastan in the U.S. and Canada as an...
BioCentury | Dec 13, 2010
Finance

Thelin's Last Breath

...requested an additional pivotal trial. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Dec 13, 2010
Clinical News

Thelin sitaxentan update

...should conduct an additional study. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
...Sept. 30 (see BioCentury, June, 18, 2007). Pfizer gained Thelin from its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Dec 11, 2010
Company News

Pfizer withdraws PAH drug

...that requested an additional study. Pfizer, which gained the drug through its 2008 acquisition of Encysive Pharmaceuticals Inc....
BioCentury | Oct 6, 2008
Company News

Castle Biosciences management update

...Diagnostic Hired: Derek Maetzold as president and CEO, formerly VP of marketing and sales at Encysive Pharmaceuticals Inc. WIR...
BioCentury | Jun 16, 2008
Company News

Encysive, Pfizer deal

...Encysive for $2.35 per share, or about $195 million in cash (see BioCentury, April 21). Encysive Pharmaceuticals Inc....
BioCentury | Apr 24, 2008
Distillery Therapeutics

This Week in Therapeutics

...of the U.S. Thelin sitaxsentan, an endothelin A receptor antagonist that Pfizer Inc. acquired from Encysive Pharmaceuticals Inc....
BioCentury | Apr 21, 2008
Company News

Encysive, Pfizer deal

...Pfizer completed its tender offer for Encysive, acquiring 69.1 million shares (85.3%) at $2.35 for a...
...to acquire the remaining shares at $2.35 via a merger agreement (see BioCentury, Feb. 25). Encysive Pharmaceuticals Inc....
BioCentury | Apr 14, 2008
Company News

Encysive, Pfizer deal

...Encysive. At April 7, there were 67.4 million shares (83%) tendered (see BioCentury, Feb. 25). Encysive Pharmaceuticals Inc....
Items per page:
1 - 10 of 310